Analysts Anticipate VBI Vaccines Inc (NASDAQ:VBIV) Will Post Quarterly Sales of $860,000.00

Brokerages expect VBI Vaccines Inc (NASDAQ:VBIV) to post $860,000.00 in sales for the current quarter, Zacks reports. Two analysts have issued estimates for VBI Vaccines’ earnings, with the lowest sales estimate coming in at $500,000.00 and the highest estimate coming in at $1.21 million. VBI Vaccines posted sales of $640,000.00 in the same quarter last year, which suggests a positive year over year growth rate of 34.4%. The business is scheduled to issue its next quarterly earnings report on Friday, August 14th.

According to Zacks, analysts expect that VBI Vaccines will report full year sales of $3.31 million for the current year, with estimates ranging from $2.00 million to $4.62 million. For the next fiscal year, analysts forecast that the company will post sales of $6.18 million, with estimates ranging from $4.10 million to $8.25 million. Zacks’ sales averages are an average based on a survey of analysts that cover VBI Vaccines.

VBI Vaccines (NASDAQ:VBIV) last released its quarterly earnings data on Wednesday, May 6th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.01. VBI Vaccines had a negative net margin of 2,133.79% and a negative return on equity of 57.79%. The company had revenue of $0.42 million during the quarter, compared to analysts’ expectations of $0.83 million.

A number of research analysts have weighed in on VBIV shares. Oppenheimer lifted their price objective on shares of VBI Vaccines from $5.00 to $8.00 and gave the company an “outperform” rating in a report on Tuesday, June 23rd. BMO Capital Markets reiterated a “buy” rating and issued a $4.00 target price on shares of VBI Vaccines in a research report on Monday. BidaskClub upgraded shares of VBI Vaccines from a “buy” rating to a “strong-buy” rating in a research report on Thursday, June 18th. Canaccord Genuity reiterated a “buy” rating and issued a $4.00 target price on shares of VBI Vaccines in a research report on Friday, March 6th. Finally, Zacks Investment Research lowered shares of VBI Vaccines from a “strong-buy” rating to a “hold” rating in a research report on Thursday. Two investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $4.10.

VBIV traded up $0.14 on Monday, reaching $3.13. The stock had a trading volume of 11,861,720 shares, compared to its average volume of 8,141,211. VBI Vaccines has a 12-month low of $0.47 and a 12-month high of $3.50. The company has a current ratio of 1.30, a quick ratio of 1.28 and a debt-to-equity ratio of 0.01. The business’s 50-day moving average price is $2.20 and its two-hundred day moving average price is $1.47. The company has a market cap of $689.64 million, a P/E ratio of -8.94 and a beta of 1.69.

In other VBI Vaccines news, major shareholder Life Sciences Maste Perceptive purchased 9,090,909 shares of the stock in a transaction that occurred on Friday, April 24th. The shares were purchased at an average cost of $1.21 per share, for a total transaction of $10,999,999.89. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 10.00% of the company’s stock.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. State Street Corp boosted its position in VBI Vaccines by 15.1% during the first quarter. State Street Corp now owns 2,362,367 shares of the biopharmaceutical company’s stock worth $2,244,000 after acquiring an additional 310,001 shares during the last quarter. Royal Bank of Canada boosted its position in VBI Vaccines by 832.1% during the first quarter. Royal Bank of Canada now owns 35,437 shares of the biopharmaceutical company’s stock worth $34,000 after acquiring an additional 31,635 shares during the last quarter. Integrated Wealth Concepts LLC acquired a new position in VBI Vaccines during the first quarter worth about $35,000. Wells Fargo & Company MN boosted its position in VBI Vaccines by 375.6% during the first quarter. Wells Fargo & Company MN now owns 106,800 shares of the biopharmaceutical company’s stock worth $102,000 after acquiring an additional 84,346 shares during the last quarter. Finally, Alliancebernstein L.P. boosted its position in VBI Vaccines by 70.7% during the first quarter. Alliancebernstein L.P. now owns 153,800 shares of the biopharmaceutical company’s stock worth $146,000 after acquiring an additional 63,700 shares during the last quarter. Hedge funds and other institutional investors own 33.88% of the company’s stock.

About VBI Vaccines

VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company offers Sci-B-Vac, a prophylactic hepatitis B vaccine for adults, children, and newborns; and eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines that closely mimic the structure of the target virus.

Recommended Story: Options Trading

Get a free copy of the Zacks research report on VBI Vaccines (VBIV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for VBI Vaccines (NASDAQ:VBIV)

Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.